Neurocrine Biosciences (BSP:N1BI34) Long-Term Capital Lease Obligation : R$1,266 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Long-Term Capital Lease Obligation?

Neurocrine Biosciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$1,266 Mil.

Neurocrine Biosciences's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 (R$432 Mil) to Sep. 2023 (R$424 Mil) but then increased from Sep. 2023 (R$424 Mil) to Dec. 2023 (R$1,266 Mil).

Neurocrine Biosciences's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (R$595 Mil) to Dec. 2022 (R$490 Mil) but then increased from Dec. 2022 (R$490 Mil) to Dec. 2023 (R$1,266 Mil).

Neurocrine Biosciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Neurocrine Biosciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Long-Term Capital Lease Obligation Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

355.86

485.66

595.46

490.45

1,265.62

Neurocrine Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															490.45	470.86	432.47	424.23	1,265.62

Neurocrine Biosciences (BSP:N1BI34) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Neurocrine Biosciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (BSP:N1BI34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NBIX:USA NB3:Germany

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines